ARCH-backed Im­muneID re­struc­tures and search­es for part­ners

Boston-area biotech Im­muneID has gone through a re­cent re­struc­tur­ing and is search­ing for part­ners on its plat­form, which was born out of the same Har­vard lab as TScan Ther­a­peu­tics.

The com­pa­ny “im­ple­ment­ed a cor­po­rate re­struc­tur­ing de­signed to align and ex­tend cur­rent cash re­sources to ad­vance its lead SSc [sys­temic scle­ro­sis] pro­gram in­to clin­i­cal de­vel­op­ment,” a com­pa­ny spokesper­son said in an emailed state­ment to End­points News. Mul­ti­ple em­ploy­ees post­ed to LinkedIn in re­cent days to say they’d been laid off from the start­up.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER